P-128 is under clinical development by GangaGen Biotechnologies and currently in Phase II for Staphylococcus aureus Infections.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Nurse loses leg after cutting foot, contracting bacterial infection while on Florida vacation SURPRISE, Ariz. ( KPHO /Gray News) – A nurse in Arizona is adjusting to his new normal after losing his ...

In the realm of orthopedic medicine, the challenge of managing infected bone defects (IBDs) has persisted as a significant ...

The multivalent toxoid vaccine candidate from LimmaTech Biologics AG is designed to prevent skin and soft-tissue infections ...

In the realm of orthopedic medicine, the challenge of managing infected bone defects (IBDs) has persisted as a significant hurdle. The advent of ...

Mercy Health — Regional Medical Center is pushing back against the safety grades it received from Leapfrog, an independent watchdog organization that grades hospitals on how well they prevent medical ...

A letter published today in Emerging Infectious Diseases describes a case of vancomycin-resistant Staphylococcus aureus (VRSA ...

Basilea enters agreement with Innoviva Specialty Therapeutics for commercialization of antibiotic Zevtera in US: Allschwil, Switzerland Tuesday, December 17, 2024, 15:00 Hrs [IST] ...

Staphylococcus aureus (S. aureus) is a major cause of skin and soft tissue infections that can sometimes lead to sepsis and toxic shock syndrome. The microbe poses a significant threat to public ...

“It is a pathogen in dire need of control because it causes significant morbidity and mortality not just in the United States ...